Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

Elizabeth K. Lee; Zhenying Tan-Wasielewski; Carol Aghajanian; Robert L. Coleman; Jennifer Curtis; Michelle S. Hirsch; Ursula A. Matulonis; Lewis C. Cantley; Gordon B. Mills; L. Austin Doyle; Joyce F. Liu

doi:10.1016/j.gore.2020.100546

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

Elizabeth K. Lee, Zhenying Tan-Wasielewski, Carol Aghajanian, Robert L. Coleman, Jennifer Curtis, Michelle S. Hirsch, Ursula A. Matulonis, Lewis C. Cantley, Gordon B. Mills, L. Austin Doyle, Joyce F. Liu

Research output: Contribution to journal › Article

Abstract

Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT pathway alterations are frequently found in several cancer types, including ovarian cancer, and thus AKT inhibition is a rational targeted therapy. Here we report the results of an abbreviated trial of AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian, fallopian tube, and primary peritoneal cancer with PTEN loss.

Original language	English (US)
Article number	100546
Journal	Gynecologic Oncology Reports
Volume	32
DOIs	https://doi.org/10.1016/j.gore.2020.100546
State	Published - May 2020

Keywords

AKT inhibitor
MK-2206
PI3K/AKT pathway
Platinum resistant ovarian cancer
PTEN
Serous ovarian carcinoma

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology

Access to Document

10.1016/j.gore.2020.100546

Fingerprint Dive into the research topics of 'Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)'. Together they form a unique fingerprint.

Cite this

Lee, E. K., Tan-Wasielewski, Z., Aghajanian, C., Coleman, R. L., Curtis, J., Hirsch, M. S., Matulonis, U. A., Cantley, L. C., Mills, G. B., Doyle, L. A., & Liu, J. F. (2020). Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). Gynecologic Oncology Reports, 32, [100546]. https://doi.org/10.1016/j.gore.2020.100546

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). / Lee, Elizabeth K.; Tan-Wasielewski, Zhenying; Aghajanian, Carol; Coleman, Robert L.; Curtis, Jennifer; Hirsch, Michelle S.; Matulonis, Ursula A.; Cantley, Lewis C.; Mills, Gordon B.; Doyle, L. Austin; Liu, Joyce F.

In: Gynecologic Oncology Reports, Vol. 32, 100546, 05.2020.

Research output: Contribution to journal › Article

Lee, EK, Tan-Wasielewski, Z, Aghajanian, C, Coleman, RL, Curtis, J, Hirsch, MS, Matulonis, UA, Cantley, LC, Mills, GB, Doyle, LA & Liu, JF 2020, 'Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)', Gynecologic Oncology Reports, vol. 32, 100546. https://doi.org/10.1016/j.gore.2020.100546

Lee EK, Tan-Wasielewski Z, Aghajanian C, Coleman RL, Curtis J, Hirsch MS et al. Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). Gynecologic Oncology Reports. 2020 May;32. 100546. https://doi.org/10.1016/j.gore.2020.100546

Lee, Elizabeth K. ; Tan-Wasielewski, Zhenying ; Aghajanian, Carol ; Coleman, Robert L. ; Curtis, Jennifer ; Hirsch, Michelle S. ; Matulonis, Ursula A. ; Cantley, Lewis C. ; Mills, Gordon B. ; Doyle, L. Austin ; Liu, Joyce F. / Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). In: Gynecologic Oncology Reports. 2020 ; Vol. 32.

@article{d361d41f76ca43d8bcd8d571b34f7750,

title = "Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)",

abstract = "Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT pathway alterations are frequently found in several cancer types, including ovarian cancer, and thus AKT inhibition is a rational targeted therapy. Here we report the results of an abbreviated trial of AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian, fallopian tube, and primary peritoneal cancer with PTEN loss.",

keywords = "AKT inhibitor, MK-2206, PI3K/AKT pathway, Platinum resistant ovarian cancer, PTEN, Serous ovarian carcinoma",

author = "Lee, {Elizabeth K.} and Zhenying Tan-Wasielewski and Carol Aghajanian and Coleman, {Robert L.} and Jennifer Curtis and Hirsch, {Michelle S.} and Matulonis, {Ursula A.} and Cantley, {Lewis C.} and Mills, {Gordon B.} and Doyle, {L. Austin} and Liu, {Joyce F.}",

year = "2020",

month = may,

doi = "10.1016/j.gore.2020.100546",

language = "English (US)",

volume = "32",

journal = "Gynecologic Oncology Reports",

issn = "2211-338X",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

AU - Lee, Elizabeth K.

AU - Tan-Wasielewski, Zhenying

AU - Aghajanian, Carol

AU - Coleman, Robert L.

AU - Curtis, Jennifer

AU - Hirsch, Michelle S.

AU - Matulonis, Ursula A.

AU - Cantley, Lewis C.

AU - Mills, Gordon B.

AU - Doyle, L. Austin

AU - Liu, Joyce F.

PY - 2020/5

Y1 - 2020/5

N2 - Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT pathway alterations are frequently found in several cancer types, including ovarian cancer, and thus AKT inhibition is a rational targeted therapy. Here we report the results of an abbreviated trial of AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian, fallopian tube, and primary peritoneal cancer with PTEN loss.

AB - Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT pathway alterations are frequently found in several cancer types, including ovarian cancer, and thus AKT inhibition is a rational targeted therapy. Here we report the results of an abbreviated trial of AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian, fallopian tube, and primary peritoneal cancer with PTEN loss.

KW - AKT inhibitor

KW - MK-2206

KW - PI3K/AKT pathway

KW - Platinum resistant ovarian cancer

KW - PTEN

KW - Serous ovarian carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85079428988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079428988&partnerID=8YFLogxK

U2 - 10.1016/j.gore.2020.100546

DO - 10.1016/j.gore.2020.100546

M3 - Article

AN - SCOPUS:85079428988

VL - 32

JO - Gynecologic Oncology Reports

JF - Gynecologic Oncology Reports

SN - 2211-338X

M1 - 100546

ER -